North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share and Forecast 2020-2026
The North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.4% over the forecast period (2020-2026). The growth of the North America dipeptidyl peptidase 4 (DPP-4) inhibitors industry in the region is primarily driven by the increase in the number of cases of diabetes type 2 in the North American region. As per the International Diabetes Federation IDF 2019, over 31.0 million people were suffering from diabetes in the US and approximately 16 million people in Canada. The total number of cases in the US is projected to witness an upsurge owing to the changing lifestyles of the people, thus, it is projected by the IDF that in 2030 the total number of cases is expected to surpass 34.4 million and over 36.0 million cases in 2045. Thus, an increased number is likely to create a scope for market growth.
To Request a Sample of our Report on North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market: https://www.omrglobal.com/request-sample/north-america-europe-dipeptidyl-peptidase-4-inhibitors-market
However, there are severe side
effects associated with the consumption of the drug is likely to challenge the
growth of the market. Additionally, in 2015, the US FDA had warned regarding the
intake of the DPP-4 inhibitors. It results in severe joint pain. Nevertheless,
the drug can be taken with a specific diet and exercise for lowering the blood
sugar levels in adults suffering from type 2 diabetes. Furthermore, the
contributions by the key players in order to develop advanced and safe drugs
may create significant scope for the market growth over the forecast period.
Market Coverage
·
Market number available for – 2019-2026
·
Base year- 2019
·
Forecast period- 2020-2026
·
Segment Covered- By Type
·
Regions Covered- North America
·
Competitive Landscape- Boehringer Ingelheim
International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily &
Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp.,
and Takeda Pharmaceutical Co. among others
A full Report of North
America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is Available at:
https://www.omrglobal.com/industry-reports/north-america-europe-dipeptidyl-peptidase-4-inhibitors-market
North America
Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation
By Type
·
Sitagliptin
·
Vildagliptin
·
Saxagliptin
·
Linagliptin
·
Gemigliptin
·
Anagliptin
·
Teneligliptin
·
Others
North America
Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Countries
Covered
·
US
·
Canada
Company Profiles
·
AstraZeneca Plc
·
Boehringer Ingelheim International GmbH
·
Bristol Myers Squibb Co.
·
Eli Lily & Co.
·
GlaxoSmithKline Plc
·
LG Life Sciences Ltd.
·
Merck & Co.
·
Novartis AG
·
Pfizer Inc.
·
Sanofi SA
·
SatRx LLC
·
Takeda Pharmaceutical Co.
Reasons
to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For
More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/north-america-europe-dipeptidyl-peptidase-4-inhibitors-market
About Orion
Market Research
Orion Market Research (OMR) is a market research and consulting
company known for its crisp and concise reports. The company is equipped with
an experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment